![](/images/graphics-bg.png)
Disseminated Intravascular Coagulation as an Initial Manifestation of Metastatic Prostate Cancer Emergently Treated with Docetaxel-Based Chemotherapy
المؤلفون المشاركون
Levin, Miles B.
Agrawal, Kavita
Agrawal, Nirav
المصدر
Case Reports in Oncological Medicine
العدد
المجلد 2019، العدد 2019 (31 ديسمبر/كانون الأول 2019)، ص ص. 1-6، 6ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2019-04-24
دولة النشر
مصر
عدد الصفحات
6
التخصصات الرئيسية
الملخص EN
A 70-year-old male presented with hematuria and bruising of arms and legs for the last three days.
He also complained of urinary frequency and hesitancy and weight loss of 40 pounds over a span of four months.
Initial blood tests showed prothrombin time (PT) of 25.1 seconds, international normalized ratio (INR) of 2.5, partial thromboplastin time (PTT) of 43.9 seconds, fibrinogen of 60 mg/dl, fibrin degradation products (FDP) of more than 20 μg/ml, and platelets of 88,000/μl.
The impression was disseminated intravascular coagulation (DIC).
A search was initiated to determine the underlying etiology precipitating DIC.
Due to urinary symptoms and weight loss, prostate-specific antigen (PSA) was ordered.
PSA was elevated at 942 μg/dl.
Computed tomography (CT) of the abdomen and pelvis without contrast showed an enlarged prostate with mass effect on the bladder base, left-sided hydronephrosis, and numerous enlarged pelvic lymph nodes.
A bone scan of the whole body showed increased sclerosis of the L3 vertebral body.
There was a concern for metastatic prostate cancer precipitating DIC.
On first admission, our patient’s DIC was stabilized with FFP and cryoprecipitate transfusions.
He refused chemotherapy, and degarelix was not economically feasible.
Accordingly, he was started on androgen deprivation therapy (ADT), bicalutamide, and leuprolide as an inpatient, pending the tissue biopsy.
The patient refused a prostate biopsy.
A bone marrow biopsy was performed which confirmed metastatic prostate adenocarcinoma.
The patient was stable for discharge with a plan for outpatient chemotherapy.
Subsequently, he was lost to follow-up with the oncology.
Six months after the initial presentation, he was readmitted with hematuria.
Repeat PSA worsened to 1,970 μg/dl.
Blood work was consistent with acute DIC.
He refused chemotherapy again.
So, he was restarted on ADT.
However, his hematuria and DIC panel were worsening.
He was emergently started on docetaxel as an inpatient (after patient agreement).
Within three days of starting chemotherapy, his hematuria resolved and DIC panel showed consistent improvement.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Agrawal, Kavita& Agrawal, Nirav& Levin, Miles B.. 2019. Disseminated Intravascular Coagulation as an Initial Manifestation of Metastatic Prostate Cancer Emergently Treated with Docetaxel-Based Chemotherapy. Case Reports in Oncological Medicine،Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1142023
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Agrawal, Kavita…[et al.]. Disseminated Intravascular Coagulation as an Initial Manifestation of Metastatic Prostate Cancer Emergently Treated with Docetaxel-Based Chemotherapy. Case Reports in Oncological Medicine No. 2019 (2019), pp.1-6.
https://search.emarefa.net/detail/BIM-1142023
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Agrawal, Kavita& Agrawal, Nirav& Levin, Miles B.. Disseminated Intravascular Coagulation as an Initial Manifestation of Metastatic Prostate Cancer Emergently Treated with Docetaxel-Based Chemotherapy. Case Reports in Oncological Medicine. 2019. Vol. 2019, no. 2019, pp.1-6.
https://search.emarefa.net/detail/BIM-1142023
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1142023
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)